製品番号: HY-10211

Tanespimycin

(別名: タネスピマイシン; 17-AAG; NSC 330507; CP 127374)

70 Cited Publications

カスタマーレビュー

Based on 70 publication(s) in Google Scholar

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC₅₀ of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90. Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.01%
CAS 番号: 75747-14-7
分子式: C₃₁H₄₃N₃O₈
分子量:585.69

保管条件:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Tanespimycin 構造式

CAS 番号: 75747-14-7

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
- 臨床実験
化学情報
Publications (70)
溶剤 & 溶解度
- 体外
- 体内
プロトコル
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC₅₀ of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90^[1]^[5]. Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression^[3].

IC₅₀ & Target^[5]

HSP90

5 nM (IC₅₀)

Autophagy

Mitophagy

HSP アイソフォーム固有の製品をすべて表示 :

Antibiotic アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	1287 nM Compound: 2, 17-AAG	Antiproliferative activity against human A375 cells after 72 to 144 hrs by cyquant DNA dye method Antiproliferative activity against human A375 cells after 72 to 144 hrs by cyquant DNA dye method	[PMID: 19552433]
A-375	IC₅₀	32 nM Compound: 2, 17-AAG	Inhibition of Hsp90 in human A375 cells assessed as pS6 degradation after 24 hrs by high content screening Inhibition of Hsp90 in human A375 cells assessed as pS6 degradation after 24 hrs by high content screening	[PMID: 19552433]
A-375	IC₅₀	4 nM Compound: 2, 17-AAG	Inhibition of Hsp90 in human A375 cells assessed as Hsp70 induction after 24 hrs by high content screening Inhibition of Hsp90 in human A375 cells assessed as Hsp70 induction after 24 hrs by high content screening	[PMID: 19552433]
A-431	IC₅₀	0.07 μM Compound: 17-AAG	Antiproliferative activity against human A431 cells after 72 hrs Antiproliferative activity against human A431 cells after 72 hrs	[PMID: 20655237]
A-431	IC₅₀	0.069 μM Compound: 17-AAG	Cytotoxicity against human A431 cells after 72 hrs Cytotoxicity against human A431 cells after 72 hrs	[PMID: 22538015]
A-431	IC₅₀	89 nM Compound: 17-Aag	Cytotoxicity against human A431 cells after 72 hrs by MTT assay Cytotoxicity against human A431 cells after 72 hrs by MTT assay	[PMID: 25277067]
A549	IC₅₀	81 nM Compound: 17-Aag	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 25277067]
A549	IC₅₀	0.286 μM Compound: 2; 17-AAG	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 28073608]
A549	GI₅₀	0.0075 μM Compound: III; 17AAG	Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 31655430]
A549	IC₅₀	>10 μM Compound: 17-AAG	Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay	[PMID: 32663707]
A549	IC₅₀	>10 μM Compound: 4; 17-AAG	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay	[PMID: 33189438]
A549	GI₅₀	0.08 μM Compound: 1; 17-AAG	Antiproliferative activity against human A549 cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay Antiproliferative activity against human A549 cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay	[PMID: 33934008]
AU565	IC₅₀	0.003 μM Compound: 2, 17-AAG	Inhibition of Hsp90 in human AU565 cells assessed as Her2 degradation after 24 hrs by high content screening Inhibition of Hsp90 in human AU565 cells assessed as Her2 degradation after 24 hrs by high content screening	[PMID: 19552433]
AU565	IC₅₀	8 nM Compound: 2, 17-AAG	Inhibition of Hsp90 in human AU565 cells assessed as pERK degradation after 24 hrs by high content screening Inhibition of Hsp90 in human AU565 cells assessed as pERK degradation after 24 hrs by high content screening	[PMID: 19552433]
B16-F10	IC₅₀	0.2 μM Compound: 17-AAG	Antiproliferative activity against mouse B16F10 Antiproliferative activity against mouse B16F10	[PMID: 21972823]
BGC-823	IC₅₀	847 nM Compound: 17-Aag	Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay	[PMID: 25277067]
BT-474	IC₅₀	0.01 μM Compound: 17-AAG	Antiproliferative activity against human BT474 cells by MTS assay Antiproliferative activity against human BT474 cells by MTS assay	[PMID: 17488003]
BT-474	GI₅₀	5 nM Compound: 3, 17-AAG	Growth inhibition of human BT474 cells assessed as ATP level after 4 days Growth inhibition of human BT474 cells assessed as ATP level after 4 days	[PMID: 19410458]
CCRF-CEM	IC₅₀	0.1 μM Compound: 17-AAG	Antiproliferative activity against human CEM Antiproliferative activity against human CEM	[PMID: 21972823]
CNE-2	IC₅₀	3.03 μM Compound: 17-AAG	Cytotoxicity in human CNE-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human CNE-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33543615]
CNE2Z	IC₅₀	8.41 μM Compound: 17-AAG	Antiproliferative activity against human CNE2Z cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human CNE2Z cells assessed as cell growth inhibition by MTT assay	[PMID: 32527461]
DU-145	IC₅₀	68.3 μM Compound: 17-AAG	Cytotoxicity against DU145 cells after 72 hrs Cytotoxicity against DU145 cells after 72 hrs	[PMID: 17181154]
DU-145	IC₅₀	0.282 μM Compound: 2; 17-AAG	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 28073608]
ECa-109 cell line	IC₅₀	1.1 μM Compound: Tanespimycin, 17-AAG	Cytotoxicity against human ECA109 cells after 48 hrs by MTT assay Cytotoxicity against human ECA109 cells after 48 hrs by MTT assay	[PMID: 23621840]
GES1	CC₅₀	7.94 μM Compound: 4; 17-AAG	Cytotoxicity against human GES1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human GES1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 33189438]
HCC827	GI₅₀	56 nM Compound: 3, 17-AAG	Growth inhibition of human tarceva and iressa-resistant HCC827 cells assessed as ATP level after 4 days Growth inhibition of human tarceva and iressa-resistant HCC827 cells assessed as ATP level after 4 days	[PMID: 19410458]
HCT-116	GI₅₀	0.021 μM Compound: 1b 17AAG	Inhibition of HCT116 human colon cancer cell proliferation Inhibition of HCT116 human colon cancer cell proliferation	[PMID: 15955698]
HCT-116	GI₅₀	0.16 μM Compound: 17-AAG	Inhibitory concentration against cell proliferation of human HCT116 cell Inhibitory concentration against cell proliferation of human HCT116 cell	[PMID: 15974572]
HCT-116	GI₅₀	0.16 μM Compound: 17-AAG	Inhibition of cell proliferation in HCT116 human colon cancer cell line Inhibition of cell proliferation in HCT116 human colon cancer cell line	[PMID: 16202589]
HCT-116	IC₅₀	0.17 μM Compound: 17-AAG	Antiproliferative activity against HCT116 cell line Antiproliferative activity against HCT116 cell line	[PMID: 16480864]
HCT-116	GI₅₀	0.16 μM Compound: 1b, 17-AAG	Growth inhibition of human HCT116 cells after 24 hrs by SRB assay Growth inhibition of human HCT116 cells after 24 hrs by SRB assay	[PMID: 18020435]
HCT-116	IC₅₀	202 nM Compound: Tanespimycin, 17-AAG	Cytotoxicity against human HCT116 cells after 72 hrs Cytotoxicity against human HCT116 cells after 72 hrs	[PMID: 19231864]
HCT-116	IC₅₀	56.5 nM Compound: 17-AAG	Growth inhibition of human HCT116 cells after 24 hrs by [3H]thymidine uptake assay Growth inhibition of human HCT116 cells after 24 hrs by [3H]thymidine uptake assay	[PMID: 20014866]
HCT-116	IC₅₀	0.145 μM Compound: 17-AAG	Antiproliferative activity against human HCT116 Antiproliferative activity against human HCT116	[PMID: 21972823]
HCT-116	GI₅₀	0.34 μM Compound: III; 17AAG	Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 31655430]
HCT-116	GI₅₀	0.34 μM Compound: 1; 17-AAG	Antiproliferative activity against human HCT116 cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay Antiproliferative activity against human HCT116 cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay	[PMID: 33934008]
HCT-15	IC₅₀	1487 nM Compound: 2, 17-AAG	Antiproliferative activity against human HCT15 cells after 72 to 144 hrs by cyquant DNA dye method Antiproliferative activity against human HCT15 cells after 72 to 144 hrs by cyquant DNA dye method	[PMID: 19552433]
HCT-15	IC₅₀	0.41 μM Compound: 17-AAG	Antiproliferative activity against human HCT15 Antiproliferative activity against human HCT15	[PMID: 21972823]
HeLa	IC₅₀	108.2 μM Compound: 17-AAG	Cytotoxicity against HeLa cells after 72 hrs Cytotoxicity against HeLa cells after 72 hrs	[PMID: 17181154]
HeLa	IC₅₀	128 nM Compound: 17-Aag	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 25277067]
HeLa	IC₅₀	0.2 μM Compound: 17-AAG	Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay	[PMID: 27266997]
HeLa	IC₅₀	>1000 μM Compound: III; 17AAG	Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate measured after 30 mins by fluorescence assay Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate measured after 30 mins by fluorescence assay	[PMID: 31655430]
HeLa	IC₅₀	19.4 μM Compound: 17-AAG	Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33543615]
Hep 3B2	GI₅₀	0.08 μM Compound: 1; 17-AAG	Antiproliferative activity against human Hep3B cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay Antiproliferative activity against human Hep3B cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay	[PMID: 33934008]
HepG2	IC₅₀	91 nM Compound: 17-Aag	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 25277067]
HepG2	IC₅₀	0.32 μM Compound: 17-AAG	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition by MTT assay	[PMID: 32527461]
HepG2	IC₅₀	0.33 μM Compound: 4; 17-AAG	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay	[PMID: 33189438]
HepG2	IC₅₀	8 μM Compound: 17-AAG	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33543615]
HL-60	IC₅₀	0.06 μM Compound: 17-AAG	Antiproliferative activity against human HL60 Antiproliferative activity against human HL60	[PMID: 21972823]
HT-29	IC₅₀	0.002 μM Compound: 17-AAG	Antiproliferative activity against human HT29 cells Antiproliferative activity against human HT29 cells	[PMID: 17488003]
HT-29	IC₅₀	0.1 nM Compound: 2, 17-AAG	Antiproliferative activity against human HT-29 cells after 72 to 144 hrs by cyquant DNA dye method Antiproliferative activity against human HT-29 cells after 72 to 144 hrs by cyquant DNA dye method	[PMID: 19552433]
HT-29	IC₅₀	0.01 μM Compound: 17-AAG	Antiproliferative activity against human HT-29 Antiproliferative activity against human HT-29	[PMID: 21972823]
HUVEC	IC₅₀	282 nM Compound: 17-Aag	Cytotoxicity against HUVEC cells after 72 hrs by MTT assay Cytotoxicity against HUVEC cells after 72 hrs by MTT assay	[PMID: 25277067]
HUVEC	GI₅₀	<0.1 μM Compound: 1; 17-AAG	Antiproliferative activity against human HUVEC cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay Antiproliferative activity against human HUVEC cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay	[PMID: 33934008]
K562	GI₅₀	48 nM Compound: 3, 17-AAG	Growth inhibition of human K562 cells assessed as ATP level after 4 days Growth inhibition of human K562 cells assessed as ATP level after 4 days	[PMID: 19410458]
K562	IC₅₀	126 nM Compound: 2, 17-AAG	Antiproliferative activity against human K562 cells after 72 to 144 hrs by cyquant DNA dye method Antiproliferative activity against human K562 cells after 72 to 144 hrs by cyquant DNA dye method	[PMID: 19552433]
K562	IC₅₀	0.15 μM Compound: 1, 17-AAG	Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by trypan blue exclusion assay Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by trypan blue exclusion assay	[PMID: 24565573]
L02	IC₅₀	99 nM Compound: 17-Aag	Cytotoxicity against human HL7702 cells after 72 hrs by MTT assay Cytotoxicity against human HL7702 cells after 72 hrs by MTT assay	[PMID: 25277067]
L02	CC₅₀	11.65 μM Compound: 4; 17-AAG	Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 33189438]
LNCaP	IC₅₀	82 nM Compound: 2, 17-AAG	Antiproliferative activity against human LNCAP cells after 72 to 144 hrs by cyquant DNA dye method Antiproliferative activity against human LNCAP cells after 72 to 144 hrs by cyquant DNA dye method	[PMID: 19552433]
LNCaP	IC₅₀	0.16 μM Compound: 17-AAG	Cytotoxicity against human LNCAP cells after 72 hrs by MTT assay Cytotoxicity against human LNCAP cells after 72 hrs by MTT assay	[PMID: 25105924]
LoVo	IC₅₀	0.26 μM Compound: 4; 17-AAG	Antiproliferative activity against human LoVo cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay Antiproliferative activity against human LoVo cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay	[PMID: 33189438]
MCF7	IC₅₀	>500 μM Compound: 17AAG	Inhibition of Phoshoinositol 3 kinase from MCF-7 breast cancer cells Inhibition of Phoshoinositol 3 kinase from MCF-7 breast cancer cells	[PMID: 11294389]
MCF7	IC₅₀	0.007 μM Compound: 17-AAG	Inhibition of human recombinant HSP90 in MCF7 cells assessed as Her2 degradation Inhibition of human recombinant HSP90 in MCF7 cells assessed as Her2 degradation	[PMID: 17488003]
MCF7	IC₅₀	0.01 μM Compound: 17-AAG	Antiproliferative activity against human MCF7 cells by MTS assay Antiproliferative activity against human MCF7 cells by MTS assay	[PMID: 17488003]
MCF7	IC₅₀	0.02 μM Compound: 17-AAG	Binding affinity to human recombinant HSP90 in MCF7 cell lysates assessed as inhibition of biotinylated-geldanamycin binding Binding affinity to human recombinant HSP90 in MCF7 cell lysates assessed as inhibition of biotinylated-geldanamycin binding	[PMID: 17488003]
MCF7	IC₅₀	50 μM Compound: 17-AAG	Selectivity for HSP90 in MCF7 cells over HSP90 in NDF cells Selectivity for HSP90 in MCF7 cells over HSP90 in NDF cells	[PMID: 17488003]
MCF7	IC₅₀	15 nM Compound: 2, 17-AAG	Inhibition of Hsp90 in human MCF7 cells assessed as Her2 degradation Inhibition of Hsp90 in human MCF7 cells assessed as Her2 degradation	[PMID: 19017562]
MCF7	IC₅₀	58 nM Compound: Tanespimycin, 17-AAG	Cytotoxicity against human MCF7 cells after 72 hrs Cytotoxicity against human MCF7 cells after 72 hrs	[PMID: 19231864]
MCF7	IC₅₀	662 nM Compound: Tanespimycin, 17-AAG	Cytotoxicity against human MCF7 cells after 72 hrs in presence of NQO1 inhibitor dicoumarol Cytotoxicity against human MCF7 cells after 72 hrs in presence of NQO1 inhibitor dicoumarol	[PMID: 19231864]
MCF7	IC₅₀	0.3 nM Compound: 2, 17-AAG	Antiproliferative activity against human MCF7 cells after 72 to 144 hrs by cyquant DNA dye method Antiproliferative activity against human MCF7 cells after 72 to 144 hrs by cyquant DNA dye method	[PMID: 19552433]
MCF7	IC₅₀	12 nM Compound: 3, 17-AAG, KOS953, CNF-1010	Inhibition of HSP90-mediated client protein HER2 degradation in human MCF7 cells Inhibition of HSP90-mediated client protein HER2 degradation in human MCF7 cells	[PMID: 20055425]
MCF7	IC₅₀	0.09 μM Compound: 1b, 17-AAG	Antiproliferative activity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 21920765]
MCF7	EC₅₀	12 nM Compound: 1, 17-AAG, tanespimycin	Inhibition of HSP90alpha in human MCF7 cells assessed as degradation of Her-2 Inhibition of HSP90alpha in human MCF7 cells assessed as degradation of Her-2	[PMID: 22938030]
MCF7	IC₅₀	0.029 μM Compound: 17-AAG	Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay	[PMID: 27153346]
MCF7	IC₅₀	5 nM Compound: 17-AAG	Antiproliferative activity against human MCF7 cells measured after 5 days by MTS assay Antiproliferative activity against human MCF7 cells measured after 5 days by MTS assay	[PMID: 27153346]
MCF7	IC₅₀	0.192 μM Compound: 2; 17-AAG	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 28073608]
MCF7	IC₅₀	0.005 μM Compound: 49; 17-AAG	Antitumor activity against human MCF7 cells assessed as cell growth inhibition Antitumor activity against human MCF7 cells assessed as cell growth inhibition	[PMID: 36858050]
MCF7	IC₅₀	58 nM Compound: 2a; 17-AAG	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 39361055]
MDA-MB-231	IC₅₀	194 nM Compound: 2, 17-AAG	Antiproliferative activity against human MDA-MB-231 cells after 72 to 144 hrs by cyquant DNA dye method Antiproliferative activity against human MDA-MB-231 cells after 72 to 144 hrs by cyquant DNA dye method	[PMID: 19552433]
MDA-MB-231	IC₅₀	0.28 μM Compound: 17-AAG	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 25105924]
MDA-MB-231	IC₅₀	0.28 μM Compound: 17-Aag	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 25277067]
MDA-MB-231	IC₅₀	0.52 μM Compound: 17-AAG	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 27266997]
MDA-MB-231	IC₅₀	1.79 μM Compound: 17-AAG	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition by MTT assay	[PMID: 32527461]
MDA-MB-231	GI₅₀	0.27 μM Compound: 1; 17-AAG	Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay	[PMID: 33934008]
MDA-MB-468	IC₅₀	1500 nM Compound: Tanespimycin, 17-AAG	Cytotoxicity against NQ01-deficient human MDA468 cells after 72 hrs Cytotoxicity against NQ01-deficient human MDA468 cells after 72 hrs	[PMID: 19231864]
MDA-MB-468	GI₅₀	780 nM Compound: 3, 17-AAG	Growth inhibition of human MDA-MB-468 cells assessed as ATP level after 4 days Growth inhibition of human MDA-MB-468 cells assessed as ATP level after 4 days	[PMID: 19410458]
MDA-MB-468	IC₅₀	1.57 μM Compound: 17-AAG	Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by MTT assay	[PMID: 27153346]
MRC5	CC₅₀	14.24 μM Compound: 4; 17-AAG	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 33189438]
MV4-11	GI₅₀	11 nM Compound: 3, 17-AAG	Growth inhibition of human MV4-11 cells assessed as ATP level after 4 days Growth inhibition of human MV4-11 cells assessed as ATP level after 4 days	[PMID: 19410458]
MX1	IC₅₀	0.045 μM Compound: 17-AAG	Antiproliferative activity against human MX1 Antiproliferative activity against human MX1	[PMID: 21972823]
NCI-H1299	IC₅₀	0.2 μM Compound: 17-AAG	Antiproliferative activity against human H1299 cells after 48 hrs by resazurin dye-based fluorescence assay Antiproliferative activity against human H1299 cells after 48 hrs by resazurin dye-based fluorescence assay	[PMID: 28426997]
NCI-H1975	GI₅₀	35 nM Compound: 3, 17-AAG	Growth inhibition of human tarceva and iressa-resistant NCI-H1975 cells assessed as ATP level after 4 days Growth inhibition of human tarceva and iressa-resistant NCI-H1975 cells assessed as ATP level after 4 days	[PMID: 19410458]
NCI-H1975	GI₅₀	0.16 μM Compound: III; 17AAG	Antiproliferative activity against human NCI-H1975 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI-H1975 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 31655430]
NCI-H460	IC₅₀	255 nM Compound: 2, 17-AAG	Antiproliferative activity against human NCI-H460 cells after 72 to 144 hrs by cyquant DNA dye method Antiproliferative activity against human NCI-H460 cells after 72 to 144 hrs by cyquant DNA dye method	[PMID: 19552433]
NCI-H460	IC₅₀	0.03 μM Compound: 17-AAG	Antiproliferative activity against human NCI-H460 Antiproliferative activity against human NCI-H460	[PMID: 21972823]
NCI-H460	IC₅₀	0.01 μM Compound: 17-AAG	Cytotoxicity against human NCI-H460 cells after 72 hrs Cytotoxicity against human NCI-H460 cells after 72 hrs	[PMID: 22538015]
NCI-H596	IC₅₀	1600 nM Compound: Tanespimycin, 17-AAG	Cytotoxicity against NQ01-deficient human NCI-H596 cells after 72 hrs Cytotoxicity against NQ01-deficient human NCI-H596 cells after 72 hrs	[PMID: 19231864]
NCI-N87	GI₅₀	1 nM Compound: 3, 17-AAG	Growth inhibition of human NCI-N87 cells assessed as ATP level after 4 days Growth inhibition of human NCI-N87 cells assessed as ATP level after 4 days	[PMID: 19410458]
NCM460	CC₅₀	14.21 μM Compound: 4; 17-AAG	Cytotoxicity against human NCM460 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human NCM460 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 33189438]
OVCAR-3	IC₅₀	0.48 μM Compound: 4; 17-AAG	Antiproliferative activity against human OVCAR-3 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay Antiproliferative activity against human OVCAR-3 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay	[PMID: 33189438]
PANC-1	IC₅₀	3.21 μM Compound: 4; 17-AAG	Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay	[PMID: 33189438]
PC-3	IC₅₀	9 nM Compound: 2, 17-AAG	Antiproliferative activity against human PC3 cells after 72 to 144 hrs by cyquant DNA dye method Antiproliferative activity against human PC3 cells after 72 to 144 hrs by cyquant DNA dye method	[PMID: 19552433]
PC-3	IC₅₀	0.13 μM Compound: 17-AAG	Antiproliferative activity against human PC3 Antiproliferative activity against human PC3	[PMID: 21972823]
PC-3	IC₅₀	0.062 μM Compound: 17-AAG	Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay	[PMID: 32663707]
RPTEC	IC₅₀	0.1 μM Compound: 17-AAG	Antiproliferative activity against human RPTEC Antiproliferative activity against human RPTEC	[PMID: 17488003]
RPTEC	IC₅₀	10 μM Compound: 17-AAG	Selectivity index, ratio of IC50 for human RPTEC cells to IC50 for MCF7 cells Selectivity index, ratio of IC50 for human RPTEC cells to IC50 for MCF7 cells	[PMID: 17488003]
RPTEC	IC₅₀	50 μM Compound: 17-AAG	Selectivity index, ratio of IC50 for human RPTEC cells to IC50 for HT29 cells Selectivity index, ratio of IC50 for human RPTEC cells to IC50 for HT29 cells	[PMID: 17488003]
SGC-7901	IC₅₀	>10 μM Compound: 4; 17-AAG	Antiproliferative activity against human SGC-7901 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay Antiproliferative activity against human SGC-7901 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay	[PMID: 33189438]
SK-BR-3	IC₅₀	27 nM Compound: 17-AAG	Cytotoxicity against human SKBR3 cells after 72 hrs by celltiter-Glo assay Cytotoxicity against human SKBR3 cells after 72 hrs by celltiter-Glo assay	[PMID: 15844961]
SK-BR-3	EC₅₀	22 nM Compound: 1b, 17-AAG	Upregulation of Hsp70 in SKBR3 cells Upregulation of Hsp70 in SKBR3 cells	[PMID: 16854066]
SK-BR-3	EC₅₀	35 nM Compound: 1b, 17-AAG	Degradation of Her2 in SKBR3 cells Degradation of Her2 in SKBR3 cells	[PMID: 16854066]
SK-BR-3	GI₅₀	17 nM Compound: 1b, 17-AAG	Inhibition of human SKBR3 cell growth Inhibition of human SKBR3 cell growth	[PMID: 16854066]
SK-BR-3	IC₅₀	31 nM Compound: 2, 17-AAG	Inhibition of Her2 in human SKBR3 cells Inhibition of Her2 in human SKBR3 cells	[PMID: 19017562]
SK-BR-3	IC₅₀	33 nM Compound: 2, 17-AAG	Binding affinity to Hsp90 in human SKBR3 cells Binding affinity to Hsp90 in human SKBR3 cells	[PMID: 19017562]
SK-BR-3	IC₅₀	410 nM Compound: Tanespimycin, 17-AAG	Cytotoxicity against human SKBR3 cells after 72 hrs in presence of NQO1 inhibitor dicoumarol Cytotoxicity against human SKBR3 cells after 72 hrs in presence of NQO1 inhibitor dicoumarol	[PMID: 19231864]
SK-BR-3	IC₅₀	44 nM Compound: Tanespimycin, 17-AAG	Cytotoxicity against human SKBR3 cells after 72 hrs Cytotoxicity against human SKBR3 cells after 72 hrs	[PMID: 19231864]
SK-BR-3	IC₅₀	33 nM Compound: 1b, 17-AAG	Cytotoxicity against human SKBR3 cells after 72 hrs by celltiter-glo assay Cytotoxicity against human SKBR3 cells after 72 hrs by celltiter-glo assay	[PMID: 19405528]
SK-BR-3	EC₅₀	<0.1 μM Compound: 1, 17-AAG	Inhibition of Hsp90alpha in human SKBR3 cells assessed as ErbB2 degradation by Western blot analysis Inhibition of Hsp90alpha in human SKBR3 cells assessed as ErbB2 degradation by Western blot analysis	[PMID: 21106457]
SK-BR-3	EC₅₀	0.025 μM Compound: 1, 17-AAG	Cytotoxicity against human SKBR3 cells Cytotoxicity against human SKBR3 cells	[PMID: 21106457]
SK-BR-3	EC₅₀	0.06 μM Compound: 1, 17-AAG	Inhibition of Hsp90alpha in human SKBR3 cells assessed as up-regulation of HSP70 protein by Western blot analysis Inhibition of Hsp90alpha in human SKBR3 cells assessed as up-regulation of HSP70 protein by Western blot analysis	[PMID: 21106457]
SK-BR-3	IC₅₀	0.025 μM Compound: 17-AAG	Antiproliferative activity against human SKBR3 Antiproliferative activity against human SKBR3	[PMID: 21972823]
SK-BR-3	IC₅₀	0.038 μM Compound: 17-AAG	Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay	[PMID: 32663707]
SK-BR-3	IC₅₀	0.004 μM Compound: 49; 17-AAG	Antitumor activity against human SK-BR-3 cells assessed as cell growth inhibition Antitumor activity against human SK-BR-3 cells assessed as cell growth inhibition	[PMID: 36858050]
SK-BR-3	IC₅₀	31 nM Compound: 1b5	Inhibition of oncogene product p185 erbB-2 from human breast cancer cells(SK-BR-3 cells) at 50 mg/kg dose. Inhibition of oncogene product p185 erbB-2 from human breast cancer cells(SK-BR-3 cells) at 50 mg/kg dose.	[PMID: 7562911]
SK-BR-3	IC₅₀	31 nM Compound: 1c	In vitro inhibition of p185 erbB-2 oncoprotein in human breast cancer SK-BR-3 cells In vitro inhibition of p185 erbB-2 oncoprotein in human breast cancer SK-BR-3 cells	[PMID: 7562912]
SK-MEL-5	IC₅₀	134 nM Compound: 2, 17-AAG	Antiproliferative activity against human SK-MEL-5 cells after 72 to 144 hrs by cyquant DNA dye method Antiproliferative activity against human SK-MEL-5 cells after 72 to 144 hrs by cyquant DNA dye method	[PMID: 19552433]
SK-OV-3	EC₅₀	19 nM Compound: 1b, 17-AAG	Degradation of Her2 in SKOV3 cells Degradation of Her2 in SKOV3 cells	[PMID: 16854066]
SK-OV-3	GI₅₀	15 nM Compound: 1b, 17-AAG	Inhibition of human SKOV3 cell growth Inhibition of human SKOV3 cell growth	[PMID: 16854066]
SK-OV-3	IC₅₀	240 nM Compound: Tanespimycin, 17-AAG	Cytotoxicity against human SKOV3 cells after 72 hrs Cytotoxicity against human SKOV3 cells after 72 hrs	[PMID: 19231864]
SK-OV-3	IC₅₀	0.22 μM Compound: 17-AAG	Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay	[PMID: 32663707]
SK-OV-3	IC₅₀	240 nM Compound: 2a; 17-AAG	Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 39361055]
SMMC-7721	IC₅₀	0.19 μM Compound: 17-AAG	Antiproliferative activity against human SMMC7721 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human SMMC7721 cells assessed as cell growth inhibition by MTT assay	[PMID: 32527461]
SW480	IC₅₀	572 nM Compound: 17-Aag	Cytotoxicity against human SW480 cells after 72 hrs by MTT assay Cytotoxicity against human SW480 cells after 72 hrs by MTT assay	[PMID: 25277067]
SW480	IC₅₀	0.28 μM Compound: 17-AAG	Antiproliferative activity against human SW480 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human SW480 cells assessed as cell growth inhibition by MTT assay	[PMID: 32527461]
SW-620	IC₅₀	328 nM Compound: 2, 17-AAG	Antiproliferative activity against human SW620 cells after 72 to 144 hrs by cyquant DNA dye method Antiproliferative activity against human SW620 cells after 72 to 144 hrs by cyquant DNA dye method	[PMID: 19552433]
U-87MG ATCC	IC₅₀	>10 μM Compound: 17-AAG	Antiproliferative activity against human U-87 MG cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human U-87 MG cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay	[PMID: 32663707]

体外実験

Tanespimycin causes the degradation of HER2, Akt, and both mutant and wild-type AR and the retinoblastoma-dependent G1 growth arrest of prostate cancer cells. Tanespimycin inhibits prostate cancer cell lines with IC₅₀s ranged from 25-45 nM (LNCaP, 25 nM; LAPC-4, 40 nM; DU-145, 45 nM; and PC-3, 25 nM)^[1].
Tanespimycin (0.1-1 μM) induces a nearly complete loss of ErbB2 on ErbB2-overexpressing breast cancer cells^[2]. Tanespimycin inhibits cell growth and induces G2/M cell cycle arrest and apoptosis in CCA cells together with the down-regulation of Bcl-2, Survivin and Cyclin B1, and the up-regulation of cleaved PARP^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Tanespimycin (25-200 mg/kg, i.p.) causes a dose-dependent decline in AR, HER2, and Akt expression in prostate cancer xenografts. Tanespimycin treatment at doses sufficient to induce AR, HER2, and Akt degradation results in the dose-dependent inhibition of androgen-dependent and -independent prostate cancer xenograft growth without toxicity^[1].
Tanespimycin (60 mg/kg) with Rapamycin (30 mg/kg) inhibits A549 and MDA-MB-231 tumor growth and effects tumor cures in MDA-MB-231 tumor-bearing animals by tail vein injection^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 75747-14-7
性状 Solid
分子量 585.69
分子式 C₃₁H₄₃N₃O₈
Color Purple to purplish red
SMILES

O=C(C(NC(/C(C)=C/C=C\[C@H](OC)[C@H](/C(C)=C/[C@@H]([C@H]([C@H](C[C@@H](C1)C)OC)O)C)OC(N)=O)=O)=CC2=O)C1=C2NCC=C
別名

タネスピマイシン; 17-AAG; NSC 330507; CP 127374
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (70)

All IHCWB

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

A Cullin 5-based complex serves as an essential modulator of ORF9b stability in SARS-CoV-2 replication. [Abstract]

2024 Jun 28;9(1):159. PMID: 38937432
Nat Biotechnol

A rapid imaging-based screen for induced-proximity degraders identifies a potent degrader of oncoprotein SKP2. [Abstract]

2025 Sep 10. PMID: 40931108
Blood

Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia. [Abstract]

2019 Oct 17;134(16):1323-1336. PMID: 31492675
Nat Commun

Nascent liver proteome reveals enzymes and transcription regulators under physiological and alcohol exposure conditions. [Abstract]

2025 Aug 26;16(1):7945. PMID: 40858584
Nat Commun

Generation of whole tumor cell vaccine for on-demand manipulation of immune responses against cancer under near-infrared laser irradiation. [Abstract]

2023 Jul 26;14(1):4505. PMID: 37495590
Redox Biol

Supplementing sialic acid analogs overcomes radiotherapy resistance in triple-negative breast cancer by exacerbating ER stress. [Abstract]

2025 Jun 7:85:103712. PMID: 40505348
Mol Cell

UbiREAD deciphers proteasomal degradation code of homotypic and branched K48 and K63 ubiquitin chains. [Abstract]

2025 Mar 20:S1097-2765(25)00152-2. PMID: 40132582
Cardiovasc Diabetol

Pgk1 activation restores endothelial metabolic homeostasis to alleviate vascular aging and atherosclerosis. [Abstract]

2025 Nov 8;24(1):427. PMID: 41206451
Nucleic Acids Res

Necdin regulates BMAL1 stability and circadian clock through SGT1-HSP90 chaperone machinery. [Abstract]

2020 Aug 20;48(14):7944-7957. PMID: 32667666
Theranostics

3'-epi-12β-hydroxyfroside, a new cardenolide, induces cytoprotective autophagy via blocking the Hsp90/Akt/mTOR axis in lung cancer cells. [Abstract]

2018 Feb 15;8(7):2044-2060. PMID: 29556372
Acta Pharm Sin B

2026 Feb 2026 Feb 26.
J Exp Clin Cancer Res

Inflammatory interferon activates HIF-1α-mediated epithelial-to-mesenchymal transition via PI3K/AKT/mTOR pathway. [Abstract]

2018 Mar 27;37(1):70. PMID: 29587825

Tanespimycin purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2018 Mar 27;37(1):70. [Abstract]

Cells are first treated with commercially available HIF-1α inhibitors, including compounds targeting Top1 (Camptothecin, CPT), Top2 (VP; MX) and HSP90 (17-AAG) as well as 2-ME, and then subjected to Western blotting analysis.
Adv Sci (Weinh)

A Prion-Like Domain in EBV EBNA1 Promotes Phase Separation and Enables SRRM1 Splicing. [Abstract]

2025 Jul 29:e01977. PMID: 40729735
Adv Sci (Weinh)

Intermediate Filament Protein BFSP1 Maintains Oocyte Asymmetric Division by Modulating Spindle Length. [Abstract]

2025 May 11:e2504066. PMID: 40349178
MedComm (2020)

Full-active pharmaceutical ingredient nanosensitizer for augmented photoimmunotherapy by synergistic mitochondria targeting and immunogenic death inducing. [Abstract]

2024 Nov 9;5(11):e756. PMID: 39525955
Cell Death Dis

The antitumor natural product tanshinone IIA inhibits protein kinase C and acts synergistically with 17-AAG. [Abstract]

2018 Feb 7;9(2):165. PMID: 29416003

Tanespimycin purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Feb 7;9(2):165. [Abstract]

Western blot analysis of Hsp70 protein and Hsp90 client proteins IKK and EGFR after 24 h Tan IIA treatment. The Hsp90 inhibitor 17-AAG (10 μM) is included as a positive control
Cancer Lett

Mutant p53 activates hnRNPA2B1-AGAP1-mediated exosome formation to promote esophageal squamous cell carcinoma progression. [Abstract]

2023 May 28:562:216154. PMID: 37030635
Int J Biol Sci

Timosaponin AIII promotes non-small-cell lung cancer ferroptosis through targeting and facilitating HSP90 mediated GPX4 ubiquitination and degradation. [Abstract]

2023 Feb 27;19(5):1471-1489. PMID: 37056925
Cell Commun Signal

ONC212, alone or in synergistic conjunction with Navitoclax (ABT-263), promotes cancer cell apoptosis via unconventional mitochondrial-independent caspase-3 activation. [Abstract]

2024 Sep 13;22(1):441. PMID: 39272099
Phytomedicine

Bruceine A ameliorates ulcerative colitis via macrophage polarization: Targeting HSP90-mediated IL-17 signaling and NF-κB activation. [Abstract]

2025 Nov:147:157200. PMID: 40907407
Phytomedicine

Parthenolide inhibits Hsp90α ATPase activity and overcomes acquired BRAF-inhibitor resistance in cutaneous melanoma. [Abstract]

2025 Oct:146:157151. PMID: 40815947
Phytomedicine

Celastrol induces DNA damage and cell death in BCR-ABL T315I-mutant CML by targeting YY1 and HMCES. [Abstract]

2024 Nov:134:155937. PMID: 39255723
Adv Healthc Mater

Peptomer Linkers Enable Kinetic Control over Co-Delivery of Multiple Chemotherapeutics. [Abstract]

2025 Dec 30:e04277. PMID: 41472401
J Transl Med

HSP90 inhibitor 17AAG attenuates sevoflurane-induced neurotoxicity in rats and human neuroglioma cells via induction of HSP70. [Abstract]

2020 Apr 15;18(1):166. PMID: 32293462
Nano Res

15 December 2021.
Int J Biol Macromol

17-AAG promotes the degradation of HSP90 client METTL3 to suppress MYC RNA m6A modification and expression in colorectal cancer. [Abstract]

2025 Dec 3;337(Pt 1):149421. PMID: 41349747
Int J Mol Med

Irisin attenuates acute lung injury by suppressing the pyroptosis of alveolar macrophages. [Abstract]

2023 Apr;51(4):32. PMID: 36896789

Tanespimycin purchased from MedChemExpress. Usage Cited in: Int J Mol Med. 2023 Apr;51(4):32. [Abstract]

Tanespimycin (17‑AAG) inhibits the levels of HSP90 and NLRP3, and decreases GSDMD expression, in MH‑S cells.
Aging Cell

Decreased Glucose Metabolism and Declined Chaperones Are Unique Features Required for the Survival of Senescent Fibroblasts and Pyruvate Dehydrogenase Is a Potent Senolytic Target. [Abstract]

2026 Mar;25(3):e70434. PMID: 41786630
Mol Cancer Ther

Cotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer. [Abstract]

2016 Sep;15(9):2107-18. PMID: 27390342

Tanespimycin purchased from MedChemExpress. Usage Cited in: Mol Cancer Ther. 2016 Sep;15(9):2107-18. [Abstract]

Combination of MDV3100 and 17-AAG leads to decreased AR protein level and transcriptional activity. (A&B) LNCaP (A) and C4-2 (B) cells are treated as indicated for 24 hr, followed by IB against AR, PSA and CHIP. (C&D) 22RV1 (C) and MR49F (D) cells are treated as indicated for 24 hr, followed by IB against AR and HSP90. (E) C4-2 cells are treated as indicated for 24 hr, fractionated into cytoplasm and nuclear, followed by IB against AR and Plk1.
Virulence

Differential roles of HSP70 and HSP90 in Senecavirus A infection: IRES-dependent translational regulation and viral replication mechanisms. [Abstract]

2026 Dec;17(1):2605380. PMID: 41412139
Biochem Pharmacol

The 'ABC' of split-nanoluciferase HIF heterodimerization bioassays: Applications, Benefits & Considerations. [Abstract]

2024 Aug 9:116478. PMID: 39128589
Cells

Search for Synergistic Drug Combinations to Treat Chronic Lymphocytic Leukemia. [Abstract]

2022 Nov 18;11(22):3671. PMID: 36429097
Pharm Biol

Berberine regulates the Notch1/PTEN/PI3K/AKT/mTOR pathway and acts synergistically with 17-AAG and SAHA in SW480 colon cancer cells. [Abstract]

2021 Dec;59(1):21-30. PMID: 33417512
Front Microbiol

EGFR Activation Impairs Antiviral Activity of Interferon Signaling in Brain Microvascular Endothelial Cells During Japanese Encephalitis Virus Infection. [Abstract]

2022 Jun 30;13:894356. PMID: 35847084
Commun Biol

A small-molecule compound D6 overcomes EGFR-T790M-mediated resistance in non-small cell lung cancer. [Abstract]

2021 Dec 13;4(1):1391. PMID: 34903832
Commun Biol

Heat shock protein 90-targeted photodynamic therapy enables treatment of subcutaneous and visceral tumors. [Abstract]

2020 May 8;3(1):226. PMID: 32385408
Pharmaceuticals (Basel)

Esterase-Responsive Polyglycerol-Based Nanogels for Intracellular Drug Delivery in Rare Gastrointestinal Stromal Tumors. [Abstract]

2023 Nov 16;16(11):1618. PMID: 38004483
Front Endocrinol

Regulation of the EGFR Pathway by HSP90 Is Involved in the Pathogenesis of Cushing's Disease. [Abstract]

2021 Jan 18:11:601984. PMID: 33537004
Int Immunopharmacol

Covalently targeting HSP90 with a natural small-molecule costunolide to inhibit necroptosis and ulcerative colitis. [Abstract]

2026 Apr 1:174:116348. PMID: 41687519
J Pathol

Genetic deletion of histone deacetylase 6 prevents peritoneal fibrosis via suppression of heat shock protein 90 deacetylation. [Abstract]

2025 Aug;266(4-5):447-464. PMID: 40539829
J Clin Endocrinol Metab

PCSK1N as a tumor size marker and an ER stress response protein in corticotroph pituitary adenomas. [Abstract]

2024 Sep 17:dgae643. PMID: 39288010
Biofactors

Andrographolide Promotes Ferroptosis in Pancreatic Cancer via Targeting and Activating HSP90/GPX4 Ubiquitination. [Abstract]

2025 Nov-Dec;51(6):e70063. PMID: 41292183
Molecules

Vitexin Regulates Heat Shock Protein Expression by Modulating ROS Levels Thereby Protecting against Heat-Stress-Induced Apoptosis. [Abstract]

2023 Nov 17;28(22):7639. PMID: 38005362
Biochim Biophys Acta Mol Basis Dis

Small extracellular vesicles from HO-1 modified BMMSCs alleviate steatotic liver grafts ischemia-reperfusion injury by delivering PDIA4 to promote reparative macrophage polarization. [Abstract]

2025 Jun 9;1871(7):167947. PMID: 40494182
Sci Rep

Elucidating host cell response pathways and repurposing therapeutics for SARS-CoV-2 and other coronaviruses. [Abstract]

2022 Nov 5;12(1):18811. PMID: 36335206
Cancers (Basel)

HSP90α Mediates Sorafenib Resistance in Human Hepatocellular Carcinoma by Necroptosis Inhibition under Hypoxia. [Abstract]

2021 Jan 11;13(2):243. PMID: 33440739
Cell Signal

Gastric cancer derived mesenchymal stem cells promoted DNA repair and cisplatin resistance through up-regulating PD-L1/Rad51 in gastric cancer. [Abstract]

2023 Jun:106:110639. PMID: 36842523
Cell Signal

Heat shock protein 90 inhibitor ameliorates pancreatic fibrosis by degradation of transforming growth factor-β receptor. [Abstract]

2021 Aug:84:110001. PMID: 33812911
iScience

Deficiency in Prader-Willi syndrome gene necdin leads to attenuated cardiac contractility. [Abstract]

2024 May 14;27(6):109974. PMID: 38832028
BMJ Open Diabetes Res Care

Extracellular Hsp90α, which participates in vascular inflammation, is a novel serum predictor of atherosclerosis in type 2 diabetes. [Abstract]

2022 Jan;10(1):e002579. PMID: 35091448
Front Mol Neurosci

Inhibition of Heat Shock Protein 90 by 17-AAG Reduces Inflammation via P2X7 Receptor/NLRP3 Inflammasome Pathway and Increases Neurogenesis After Subarachnoid Hemorrhage in Mice. [Abstract]

2018 Nov 6;11:401. PMID: 30459553

Tanespimycin purchased from MedChemExpress. Usage Cited in: Front Mol Neurosci. 2018 Nov 6;11:401. [Abstract]

Effects of 17-AAG on neurogenesis 4 weeks after SAH.
J Virol

Heat shock protein 90 chaperone activity is required for hepatitis A virus replication. [Abstract]

2025 Jun 5:e0050225. PMID: 40470959
J Proteome Res

Quantitative Proteomics of the CDK9 Interactome Reveals a Function of the HSP90-CDC37-P-TEFb Complex for BETi-Induced HIV-1 Latency Reactivation. [Abstract]

2023 Sep 1;22(9):2880-2889. PMID: 37540094
Viruses

Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2. [Abstract]

2021 Apr 2;13(4):610. PMID: 33918368
Toxicol Appl Pharmacol

CDKN3 promoted triple-negative breast cancer by inhibiting ferroptosis through the upregulation of HSP90. [Abstract]

2026 Jan:506:117629. PMID: 41207514
Am J Cancer Res

The small-molecule drug homoharringtonine targets HSF1 to suppress pancreatic cancer progression. [Abstract]

2024 May 15;14(5):2072-2087. PMID: 38859866
PLoS One

The heat shock protein 90 inhibitor RGRN-305 attenuates SARS-CoV-2 spike protein-induced inflammation in vitro but lacks effectiveness as COVID-19 treatment in mice. [Abstract]

2024 Sep 26;19(9):e0310915. PMID: 39325762
Vet Microbiol

HSP90 inhibitors 17-AAG and VER-82576 inhibit porcine deltacoronavirus replication in vitro. [Abstract]

2022 Feb:265:109316. PMID: 34954542
Prostate

Diptoindonesin G antagonizes AR signaling and enhances the efficacy of antiandrogen therapy in prostate cancer. [Abstract]

2022 Jun;82(8):917-932. PMID: 35322879
Mamm Genome

Alantolactone curbs the malignant progression of bladder cancer partly via the HSP90AB1/LRP5/β-catenin axis. [Abstract]

2025 Dec 23;37(1):20. PMID: 41436627
Biochem Biophys Res Commun

7-aminocephalosporanic acid, a novel HSP90β inhibitor, attenuates HFD-induced hepatic steatosis. [Abstract]

2022 Sep 24:622:184-191. PMID: 35932530
Oncol Lett

Synergistic inhibition of the growth of MDA-MB-231 cells in triple-negative breast cancer by salinomycin combined with 17-AAG and its mechanism. [Abstract]

2022 Apr;23(4):138. PMID: 35317027
bioRxiv

2025 Oct 2.
bioRxiv

Episodic pain in Fabry disease is mediated by a heat shock protein-TRPA1 axis. [Abstract]

2025 Mar 26:2025.02.20.639340. PMID: 40060522
bioRxiv

2024 October 06.
bioRxiv

Low-Cost Robotic Manipulation of Live Microtissues for Cancer Drug Testing. [Abstract]

2024 Aug 6:2024.03.21.586169. PMID: 38586030
Patent

US20220211630A1.
bioRxiv

January 21, 2022.
Research Square Preprint

2021 Jun.
Patent

US20180263995A1.

溶剤 & 溶解度

体外:

DMSO : 50 mg/mL (85.37 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.7074 mL

8.5369 mL

17.0739 mL

5 mM

0.3415 mL

1.7074 mL

3.4148 mL

10 mM

0.1707 mL

0.8537 mL

1.7074 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 5 mg/mL (8.54 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5 mg/mL (8.54 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.62 mg/mL (2.77 mM); Clear solution

This protocol yields a clear solution of ≥ 1.62 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.2 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 10 mg/mL (17.07 mM); Suspended solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 15% Cremophor EL 85% Saline

Solubility: 5 mg/mL (8.54 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

プロトコル

Cell Assay^[1]

For the Alamar Blue proliferation assay, 2-4×10³ cells are plated in 96-well plates. Later (48 h), cells are treated with Tanespimycin for 96 h or 0.01% DMSO as control. On day 4, Alamar Blue viability assay is performed as described elsewhere. IC₅₀ and IC₉₀s are calculated as the doses of Tanespimycin required to inhibit cell growth by 50 and 90%, respectively. Cell cycle distribution is assayed as described previously with a Becton Dickinson fluorescence-activated cell sorter and analyzed by the Cell Cycle Multicycle system.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Tanespimycin is dissolved in an EPL vehicle. To aid in the identification of an optimal dose and schedule, nontumor bearing mice are treated by i.p. injection with 25-200 mg/kg of Tanespimycin 5 days/week for 3 weeks or by the EPL vehicle alone. Serum samples are taken from each group, and equal volumes are pooled on days 5, 10, and 15 of treatment for serum chemistry and liver function analysis. At sacrifice, plasma samples are collected for complete blood count. A gross necropsy is performed on all of the mice, and a complete necropsy, including histopathology, is performed on 1 animal/group.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (282 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Solit DB, et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.Clin Cancer Res, 2002, 8(5), 986-993. [Content Brief]

[2]. Raja, Srikumar M., et al. 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells. Cancer Biology & Therapy (2008), 7(10), 163 [Content Brief]

[3]. Zhang J, et al. The heat shock protein 90 inhibitor 17-AAG suppresses growth and induces apoptosis in human cholangiocarcinoma cells.Clin Exp Med. 2012 Sep 7. [Content Brief]

[4]. Newman B, et al. HSP90 Inhibitor 17-AAG Selectively Eradicates Lymphoma Stem Cells.Cancer Res. 2012 Sep 1;72(17):4551-61. Epub 2012 Jun 29. [Content Brief]

[5]. Kamal A, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 2003 Sep 25;425(6956):407-10. [Content Brief]

[6]. Enomoto A, et al. The HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin modulates radiosensitivity by downregulating serine/threonine kinase 38 via Sp1 inhibition. Eur J Cancer. 2013 Nov;49(16):3547-58. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.7074 mL	8.5369 mL	17.0739 mL	42.6847 mL
	5 mM	0.3415 mL	1.7074 mL	3.4148 mL	8.5369 mL
	10 mM	0.1707 mL	0.8537 mL	1.7074 mL	4.2685 mL
	15 mM	0.1138 mL	0.5691 mL	1.1383 mL	2.8456 mL
	20 mM	0.0854 mL	0.4268 mL	0.8537 mL	2.1342 mL
	25 mM	0.0683 mL	0.3415 mL	0.6830 mL	1.7074 mL
	30 mM	0.0569 mL	0.2846 mL	0.5691 mL	1.4228 mL
	40 mM	0.0427 mL	0.2134 mL	0.4268 mL	1.0671 mL
	50 mM	0.0341 mL	0.1707 mL	0.3415 mL	0.8537 mL
	60 mM	0.0285 mL	0.1423 mL	0.2846 mL	0.7114 mL
	80 mM	0.0213 mL	0.1067 mL	0.2134 mL	0.5336 mL

Tanespimycin

70 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Tanespimycin

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Covalent Screening Library

Macrocyclic Compound Library

Antibacterial Compound Library

Endoplasmic Reticulum Stress Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Antibiotics Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Mitochondria-Targeted Compound Library

Rare Diseases Drug Library

Anti-Prostate Cancer Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Extracellular Vesicles (EVs) Compound Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

RNA Binding Bioactive Compound Library

MedChemExpress（MCE）の使用を引用している文献 Tanespimycin

HSP アイソフォーム固有の製品をすべて表示

Antibiotic アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (70)

溶剤 & 溶解度

プロトコル

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Tanespimycin 関連分類

HY-10211 関連分類